CL
VKTX icon

Choreo LLC’s Viking Therapeutics VKTX Stock Holding History

Choreo LLC’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243K Buy
+6,231
New +$201K ﹤0.01% 1441
2026
Q1 		– Sell
-6,909
Closed -$244K – 1707
2025
Q4 		$244K Buy
+6,909
New +$245K ﹤0.01% 1348

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Choreo LLC's VKTX Position: Q2 2026 in Review

Choreo LLC opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 6,231 shares worth $243K. The stake represents ﹤0.01% of the portfolio and ranks #1441 among its holdings. This is a return to the name: Choreo LLC previously reported a position in VKTX as recently as Q4 2025.

Choreo LLC first reported a position in VKTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $244K in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Choreo LLC held 6,231 shares of Viking Therapeutics worth $243K as of Q2 2026.
  • Viking Therapeutics was a new Choreo LLC position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Choreo LLC's portfolio in Q2 2026, its #1441 holding.
  • Choreo LLC first reported a position in Viking Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Choreo LLC's Viking Therapeutics position peaked at $244K in Q4 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Choreo LLC's 13F filing for Q2 2026, filed 4 Aug 2026.